NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase
13 9월 2023 - 10:00PM
NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the
“Company”), a medical technology company commercializing
neuromodulation therapies that address chronic and debilitating
conditions in children and adults, today announced that President
and Chief Executive Officer Brian Carrico and Chief Medical Officer
Dr. Adrian Miranda, will present at the upcoming Gilmartin Group
Emerging Growth Showcase on Thursday, September 21, 2023, at 9:00
am ET.
To access the live webcast, please visit the
investors page of the NeurAxis website. To ask a question, please
feel free to send your questions ahead of time to IR@neuraxis.com.
The webcast will be available for replay on NeurAxis’ investor
relations website at https://ir.neuraxis.com/.
About NeurAxis, Inc.NeurAxis,
Inc., is a medical technology company focused on neuromodulation
therapies to address chronic and debilitating conditions in
children and adults. NeurAxis is dedicated to advancing science and
leveraging evidence-based medicine to drive adoption of its
IB-Stim™ therapy, which is its proprietary Percutaneous Electrical
Nerve Field Stimulation (PENFS) technology, by the medical,
scientific, and patient communities. IB-Stim™ is FDA cleared for
functional abdominal pain associated with irritable bowel syndrome
(IBS) in adolescents 11-18 years old. Additional clinical trials of
PENFS in multiple pediatric and adult conditions with large unmet
healthcare needs are underway. For more information, please
visit http://neuraxis.com.
Contacts:
CompanyNeurAxis,
Inc.info@neuraxis.com
Investor
RelationsGilmartin
GroupIR@neuraxis.com
Neuraxis (AMEX:NRXS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Neuraxis (AMEX:NRXS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024